Wells Fargo Maintains Equal-Weight on Kimberly-Clark, Lowers Price Target to $100
Wells Fargo analyst Chris Carey maintains Kimberly-Clark (NASDAQ:KMB) with a Equal-Weight and lowers the price target from $105 to $100.
Stocks · News reference
Kimberly-Clark prepares EU concessions to win approval for its $40B Kenvue deal, following Australian divestiture demands.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Wells Fargo analyst Chris Carey maintains Kimberly-Clark (NASDAQ:KMB) with a Equal-Weight and lowers the price target from $105 to $100.
Filed: 2026-10-01 AccNo: 0001104659-26-112571 Size: 242 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
B of A Securities analyst Anna Lizzul maintains Kimberly-Clark (NASDAQ:KMB) with a Buy and lowers the price target from $122 to $120.
Kenvue (KVUE) is highlighted as a smart high-yield dividend stock with a 4.68% dividend yield and 64 consecutive years of dividend increases, making it a Dividend King. The company, spun off from Johnson & Johnson three years ago, generates steady revenue from recession-resilient consumer healthcare brands like Tylenol and Neutrogena. However, uncertainty exists due to a pending acquisition by Kimberly-Clark (KMB), another Dividend King with a 5.23% yield.